Name | Isotype | Target | NCT Number | Study Design | Clinical Trial Phase |
Nivolumab | IgG4 | PD-1 | 02576509 | RCT | III |
Pembrolizumab | IgG4 | PD1 | 02702401 | RCT | III |
Tremelimumab | IgG2 | CTLA-4 | 02519348 | RCT | II |
Durvalumab | IgG1 | PD-L1 |
|